Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event
Elevated low-density lipoprotein cholesterol (LDL-C) is a well-known culprit for atherosclerosis; however, elevated lipoprotein X (LpX), an abnormal lipoprotein as dense as LDL-C, may confound differentiation between true hyperlipidemia and cholestasis-induced hyperlipidemia. We present the case of...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2024-01-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2023.0813 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148117593194496 |
|---|---|
| author | Hardik Patel Felix Berglund Christina C. Lindenmeyer Nicholas Ruthmann |
| author_facet | Hardik Patel Felix Berglund Christina C. Lindenmeyer Nicholas Ruthmann |
| author_sort | Hardik Patel |
| collection | DOAJ |
| description | Elevated low-density lipoprotein cholesterol (LDL-C) is a well-known culprit for atherosclerosis; however, elevated lipoprotein X (LpX), an abnormal lipoprotein as dense as LDL-C, may confound differentiation between true hyperlipidemia and cholestasis-induced hyperlipidemia. We present the case of a 34-year-old man diagnosed with COVID-19–induced cholangiopathy with LpX. Despite treatment with evolocumab and plasmapheresis, the patient had persistent cholestasis and ultimately received a liver transplant, resulting in the resolution of hyperlipidemia. This case highlights the potential association between LpX and COVID-19–induced cholangiopathy, emphasizing the need for further research to better understand the underlying mechanisms and treatment options for this complex disease. |
| format | Article |
| id | doaj-art-bc2ffba0aea547c8b4371dd79128e801 |
| institution | OA Journals |
| issn | 2767-7664 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | American College of Physicians |
| record_format | Article |
| series | Annals of Internal Medicine: Clinical Cases |
| spelling | doaj-art-bc2ffba0aea547c8b4371dd79128e8012025-08-20T02:27:20ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642024-01-013110.7326/aimcc.2023.0813Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen EventHardik Patel0Felix Berglund1Christina C. Lindenmeyer2Nicholas Ruthmann31Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio2Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio3Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio2Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OhioElevated low-density lipoprotein cholesterol (LDL-C) is a well-known culprit for atherosclerosis; however, elevated lipoprotein X (LpX), an abnormal lipoprotein as dense as LDL-C, may confound differentiation between true hyperlipidemia and cholestasis-induced hyperlipidemia. We present the case of a 34-year-old man diagnosed with COVID-19–induced cholangiopathy with LpX. Despite treatment with evolocumab and plasmapheresis, the patient had persistent cholestasis and ultimately received a liver transplant, resulting in the resolution of hyperlipidemia. This case highlights the potential association between LpX and COVID-19–induced cholangiopathy, emphasizing the need for further research to better understand the underlying mechanisms and treatment options for this complex disease.https://www.acpjournals.org/doi/10.7326/aimcc.2023.0813 |
| spellingShingle | Hardik Patel Felix Berglund Christina C. Lindenmeyer Nicholas Ruthmann Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event Annals of Internal Medicine: Clinical Cases |
| title | Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event |
| title_full | Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event |
| title_fullStr | Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event |
| title_full_unstemmed | Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event |
| title_short | Lipoprotein X in the Setting of COVID-19–Induced Cholangiopathy: An Unforeseen Event |
| title_sort | lipoprotein x in the setting of covid 19 induced cholangiopathy an unforeseen event |
| url | https://www.acpjournals.org/doi/10.7326/aimcc.2023.0813 |
| work_keys_str_mv | AT hardikpatel lipoproteinxinthesettingofcovid19inducedcholangiopathyanunforeseenevent AT felixberglund lipoproteinxinthesettingofcovid19inducedcholangiopathyanunforeseenevent AT christinaclindenmeyer lipoproteinxinthesettingofcovid19inducedcholangiopathyanunforeseenevent AT nicholasruthmann lipoproteinxinthesettingofcovid19inducedcholangiopathyanunforeseenevent |